These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 18465473)

  • 1. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives.
    El-Ibiary SY; Cocohoba JM
    Eur J Contracept Reprod Health Care; 2008 Jun; 13(2):123-32. PubMed ID: 18465473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug interactions between antiretrovirals and hormonal contraceptives.
    Tseng A; Hills-Nieminen C
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):559-72. PubMed ID: 23425052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acid suppressive therapy and the effects on protease inhibitors.
    Fulco PP; Vora UB; Bearman GM
    Ann Pharmacother; 2006 Nov; 40(11):1974-83. PubMed ID: 17077173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions between hormonal contraceptives and antiretrovirals.
    Nanda K; Stuart GS; Robinson J; Gray AL; Tepper NK; Gaffield ME
    AIDS; 2017 Apr; 31(7):917-952. PubMed ID: 28060009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contraception for the HIV-positive woman: a review of interactions between hormonal contraception and antiretroviral therapy.
    Robinson JA; Jamshidi R; Burke AE
    Infect Dis Obstet Gynecol; 2012; 2012():890160. PubMed ID: 22927715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contraception in women with epilepsy: pharmacokinetic interactions, contraceptive options, and management.
    Dutton C; Foldvary-Schaefer N
    Int Rev Neurobiol; 2008; 83():113-34. PubMed ID: 18929078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of hormonal contraception on bone mineral density].
    Trémollières F
    Gynecol Obstet Fertil; 2005; 33(7-8):520-5. PubMed ID: 16005661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contraception in the context of HIV/AIDS: a review.
    Agboghoroma CO
    Afr J Reprod Health; 2011 Sep; 15(3):15-23. PubMed ID: 22574489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.
    Tittle V; Bull L; Boffito M; Nwokolo N
    Clin Pharmacokinet; 2015 Jan; 54(1):23-34. PubMed ID: 25331712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
    Kearney BP; Mathias A
    Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB; Berrisford AE; Boulle AM
    Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy.
    Nanda K; Amaral E; Hays M; Viscola MA; Mehta N; Bahamondes L
    Fertil Steril; 2008 Oct; 90(4):965-71. PubMed ID: 17880953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiretroviral HIV therapy and hormonal contraceptives].
    Thorsteinsson K; Lebech AM; Dalhoff KP; Wilken-Jensen C; Katzenstein TL
    Ugeskr Laeger; 2018 Jul; 180(30):. PubMed ID: 30037382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.